Harvard Bioscience, Inc. (NASDAQ: HBIO) Stock Competitors & Peer Comparison
See HBIO's competitors and their performance on the NASDAQ and across the wider stock market.
Peer Comparison Table: Medical - Instruments & Supplies Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for HBIO and its NASDAQ peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| HBIO | $6.00 | -3.07% | 27.3M | -16.81 | -$0.36 | N/A |
| BDX | $156.36 | +2.22% | 56.6B | 11.62 | $13.45 | +2.39% |
| BDXA | $59.24 | -2.24% | 55.9B | 45.70 | $1.30 | +2.39% |
| MDLN | $38.75 | +2.98% | 32.8B | 45.06 | $0.86 | N/A |
| WST | $328.20 | -7.67% | 23.2B | 41.19 | $7.97 | +0.26% |
| HOLX | $76.01 | +0.00% | 17B | 31.54 | $2.41 | N/A |
| COO | $70.31 | +0.11% | 13.7B | 15.42 | $4.56 | N/A |
| BDXB | $48.16 | +1.39% | 13.7B | 7.60 | $6.33 | +2.39% |
| BAX | $22.40 | +3.37% | 11.6B | 10.77 | $2.08 | +0.89% |
| ATR | $132.36 | +2.61% | 8.4B | 23.13 | $5.72 | +1.43% |
Stock Comparison
Becton, Dickinson and Company (NYSE: BDX)
HBIO vs BDX Comparison July 2026
Harvard Bioscience, Inc. (NASDAQ: HBIO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HBIO stands at 27.3M. In comparison, BDX has a market cap of 56.6B. Regarding current trading prices, HBIO is priced at $6.00 on the NASDAQ, while BDX trades at $156.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HBIO currently has a P/E ratio of -16.81, whereas BDX's P/E ratio is 11.62. In terms of profitability, HBIO's ROE is -0.73%, compared to BDX's ROE of +0.05%. Regarding short-term risk, HBIO is more volatile compared to BDX. This indicates higher risk in terms of short-term price fluctuations for HBIO.Check BDX's competition here
Becton, Dickinson and Company (NYSE: BDXA)
HBIO vs BDXA Comparison July 2026
Harvard Bioscience, Inc. (NASDAQ: HBIO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HBIO stands at 27.3M. In comparison, BDXA has a market cap of 55.9B. Regarding current trading prices, HBIO is priced at $6.00 on the NASDAQ, while BDXA trades at $59.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HBIO currently has a P/E ratio of -16.81, whereas BDXA's P/E ratio is 45.70. In terms of profitability, HBIO's ROE is -0.73%, compared to BDXA's ROE of +0.05%. Regarding short-term risk, HBIO is less volatile compared to BDXA. This indicates lower risk in terms of short-term price fluctuations for HBIO.Check BDXA's competition here
Medline Inc. (NASDAQ: MDLN)
HBIO vs MDLN Comparison July 2026
Harvard Bioscience, Inc. (NASDAQ: HBIO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HBIO stands at 27.3M. In comparison, MDLN has a market cap of 32.8B. Regarding current trading prices, HBIO is priced at $6.00 on the NASDAQ, while MDLN trades at $38.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HBIO currently has a P/E ratio of -16.81, whereas MDLN's P/E ratio is 45.06. In terms of profitability, HBIO's ROE is -0.73%, compared to MDLN's ROE of +0.07%. Regarding short-term risk, HBIO is less volatile compared to MDLN. This indicates lower risk in terms of short-term price fluctuations for HBIO.Check MDLN's competition here
West Pharmaceutical Services, Inc. (NYSE: WST)
HBIO vs WST Comparison July 2026
Harvard Bioscience, Inc. (NASDAQ: HBIO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HBIO stands at 27.3M. In comparison, WST has a market cap of 23.2B. Regarding current trading prices, HBIO is priced at $6.00 on the NASDAQ, while WST trades at $328.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HBIO currently has a P/E ratio of -16.81, whereas WST's P/E ratio is 41.19. In terms of profitability, HBIO's ROE is -0.73%, compared to WST's ROE of +0.19%. Regarding short-term risk, HBIO is less volatile compared to WST. This indicates lower risk in terms of short-term price fluctuations for HBIO.Check WST's competition here
Hologic, Inc. (NASDAQ: HOLX)
HBIO vs HOLX Comparison July 2026
Harvard Bioscience, Inc. (NASDAQ: HBIO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HBIO stands at 27.3M. In comparison, HOLX has a market cap of 17B. Regarding current trading prices, HBIO is priced at $6.00 on the NASDAQ, while HOLX trades at $76.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HBIO currently has a P/E ratio of -16.81, whereas HOLX's P/E ratio is 31.54. In terms of profitability, HBIO's ROE is -0.73%, compared to HOLX's ROE of +0.11%. Regarding short-term risk, HBIO is more volatile compared to HOLX. This indicates higher risk in terms of short-term price fluctuations for HBIO.Check HOLX's competition here
The Cooper Companies, Inc. (NASDAQ: COO)
HBIO vs COO Comparison July 2026
Harvard Bioscience, Inc. (NASDAQ: HBIO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HBIO stands at 27.3M. In comparison, COO has a market cap of 13.7B. Regarding current trading prices, HBIO is priced at $6.00 on the NASDAQ, while COO trades at $70.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HBIO currently has a P/E ratio of -16.81, whereas COO's P/E ratio is 15.42. In terms of profitability, HBIO's ROE is -0.73%, compared to COO's ROE of +0.03%. Regarding short-term risk, HBIO is more volatile compared to COO. This indicates higher risk in terms of short-term price fluctuations for HBIO.Check COO's competition here
Becton, Dickinson and Company (NYSE: BDXB)
HBIO vs BDXB Comparison July 2026
Harvard Bioscience, Inc. (NASDAQ: HBIO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HBIO stands at 27.3M. In comparison, BDXB has a market cap of 13.7B. Regarding current trading prices, HBIO is priced at $6.00 on the NASDAQ, while BDXB trades at $48.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HBIO currently has a P/E ratio of -16.81, whereas BDXB's P/E ratio is 7.60. In terms of profitability, HBIO's ROE is -0.73%, compared to BDXB's ROE of +0.05%. Regarding short-term risk, HBIO is more volatile compared to BDXB. This indicates higher risk in terms of short-term price fluctuations for HBIO.Check BDXB's competition here
Baxter International Inc. (NYSE: BAX)
HBIO vs BAX Comparison July 2026
Harvard Bioscience, Inc. (NASDAQ: HBIO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HBIO stands at 27.3M. In comparison, BAX has a market cap of 11.6B. Regarding current trading prices, HBIO is priced at $6.00 on the NASDAQ, while BAX trades at $22.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HBIO currently has a P/E ratio of -16.81, whereas BAX's P/E ratio is 10.77. In terms of profitability, HBIO's ROE is -0.73%, compared to BAX's ROE of -0.16%. Regarding short-term risk, HBIO is less volatile compared to BAX. This indicates lower risk in terms of short-term price fluctuations for HBIO.Check BAX's competition here
AptarGroup, Inc. (NYSE: ATR)
HBIO vs ATR Comparison July 2026
Harvard Bioscience, Inc. (NASDAQ: HBIO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HBIO stands at 27.3M. In comparison, ATR has a market cap of 8.4B. Regarding current trading prices, HBIO is priced at $6.00 on the NASDAQ, while ATR trades at $132.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HBIO currently has a P/E ratio of -16.81, whereas ATR's P/E ratio is 23.13. In terms of profitability, HBIO's ROE is -0.73%, compared to ATR's ROE of +0.14%. Regarding short-term risk, HBIO is more volatile compared to ATR. This indicates higher risk in terms of short-term price fluctuations for HBIO.Check ATR's competition here
Avantor, Inc. (NYSE: AVTR)
HBIO vs AVTR Comparison July 2026
Harvard Bioscience, Inc. (NASDAQ: HBIO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HBIO stands at 27.3M. In comparison, AVTR has a market cap of 7.8B. Regarding current trading prices, HBIO is priced at $6.00 on the NASDAQ, while AVTR trades at $11.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HBIO currently has a P/E ratio of -16.81, whereas AVTR's P/E ratio is 13.46. In terms of profitability, HBIO's ROE is -0.73%, compared to AVTR's ROE of -0.10%. Regarding short-term risk, HBIO is more volatile compared to AVTR. This indicates higher risk in terms of short-term price fluctuations for HBIO.Check AVTR's competition here
Repligen Corporation (NASDAQ: RGEN)
HBIO vs RGEN Comparison July 2026
Harvard Bioscience, Inc. (NASDAQ: HBIO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HBIO stands at 27.3M. In comparison, RGEN has a market cap of 7.4B. Regarding current trading prices, HBIO is priced at $6.00 on the NASDAQ, while RGEN trades at $131.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HBIO currently has a P/E ratio of -16.81, whereas RGEN's P/E ratio is 73.31. In terms of profitability, HBIO's ROE is -0.73%, compared to RGEN's ROE of +0.02%. Regarding short-term risk, HBIO is less volatile compared to RGEN. This indicates lower risk in terms of short-term price fluctuations for HBIO.Check RGEN's competition here
Teleflex Incorporated (NYSE: TFX)
HBIO vs TFX Comparison July 2026
Harvard Bioscience, Inc. (NASDAQ: HBIO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HBIO stands at 27.3M. In comparison, TFX has a market cap of 5.8B. Regarding current trading prices, HBIO is priced at $6.00 on the NASDAQ, while TFX trades at $132.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HBIO currently has a P/E ratio of -16.81, whereas TFX's P/E ratio is 12.32. In terms of profitability, HBIO's ROE is -0.73%, compared to TFX's ROE of -0.28%. Regarding short-term risk, HBIO is more volatile compared to TFX. This indicates higher risk in terms of short-term price fluctuations for HBIO.Check TFX's competition here
Bausch + Lomb Corporation (NYSE: BLCO)
HBIO vs BLCO Comparison July 2026
Harvard Bioscience, Inc. (NASDAQ: HBIO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HBIO stands at 27.3M. In comparison, BLCO has a market cap of 5.8B. Regarding current trading prices, HBIO is priced at $6.00 on the NASDAQ, while BLCO trades at $16.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HBIO currently has a P/E ratio of -16.81, whereas BLCO's P/E ratio is 24.88. In terms of profitability, HBIO's ROE is -0.73%, compared to BLCO's ROE of -0.03%. Regarding short-term risk, HBIO is more volatile compared to BLCO. This indicates higher risk in terms of short-term price fluctuations for HBIO.Check BLCO's competition here
Stevanato Group S.p.A. (NYSE: STVN)
HBIO vs STVN Comparison July 2026
Harvard Bioscience, Inc. (NASDAQ: HBIO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HBIO stands at 27.3M. In comparison, STVN has a market cap of 5.4B. Regarding current trading prices, HBIO is priced at $6.00 on the NASDAQ, while STVN trades at $19.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HBIO currently has a P/E ratio of -16.81, whereas STVN's P/E ratio is 31.81. In terms of profitability, HBIO's ROE is -0.73%, compared to STVN's ROE of +0.10%. Regarding short-term risk, HBIO is less volatile compared to STVN. This indicates lower risk in terms of short-term price fluctuations for HBIO.Check STVN's competition here
Merit Medical Systems, Inc. (NASDAQ: MMSI)
HBIO vs MMSI Comparison July 2026
Harvard Bioscience, Inc. (NASDAQ: HBIO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HBIO stands at 27.3M. In comparison, MMSI has a market cap of 4.4B. Regarding current trading prices, HBIO is priced at $6.00 on the NASDAQ, while MMSI trades at $74.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HBIO currently has a P/E ratio of -16.81, whereas MMSI's P/E ratio is 19.01. In terms of profitability, HBIO's ROE is -0.73%, compared to MMSI's ROE of +0.09%. Regarding short-term risk, HBIO is more volatile compared to MMSI. This indicates higher risk in terms of short-term price fluctuations for HBIO.Check MMSI's competition here
ICU Medical, Inc. (NASDAQ: ICUI)
HBIO vs ICUI Comparison July 2026
Harvard Bioscience, Inc. (NASDAQ: HBIO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HBIO stands at 27.3M. In comparison, ICUI has a market cap of 3.9B. Regarding current trading prices, HBIO is priced at $6.00 on the NASDAQ, while ICUI trades at $157.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HBIO currently has a P/E ratio of -16.81, whereas ICUI's P/E ratio is 19.66. In terms of profitability, HBIO's ROE is -0.73%, compared to ICUI's ROE of +0.02%. Regarding short-term risk, HBIO is less volatile compared to ICUI. This indicates lower risk in terms of short-term price fluctuations for HBIO.Check ICUI's competition here
Haemonetics Corporation (NYSE: HAE)
HBIO vs HAE Comparison July 2026
Harvard Bioscience, Inc. (NASDAQ: HBIO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HBIO stands at 27.3M. In comparison, HAE has a market cap of 3.6B. Regarding current trading prices, HBIO is priced at $6.00 on the NASDAQ, while HAE trades at $78.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HBIO currently has a P/E ratio of -16.81, whereas HAE's P/E ratio is 15.86. In terms of profitability, HBIO's ROE is -0.73%, compared to HAE's ROE of +0.11%. Regarding short-term risk, HBIO is more volatile compared to HAE. This indicates higher risk in terms of short-term price fluctuations for HBIO.Check HAE's competition here
DENTSPLY SIRONA Inc. (NASDAQ: XRAY)
HBIO vs XRAY Comparison July 2026
Harvard Bioscience, Inc. (NASDAQ: HBIO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HBIO stands at 27.3M. In comparison, XRAY has a market cap of 2.6B. Regarding current trading prices, HBIO is priced at $6.00 on the NASDAQ, while XRAY trades at $12.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HBIO currently has a P/E ratio of -16.81, whereas XRAY's P/E ratio is 9.04. In terms of profitability, HBIO's ROE is -0.73%, compared to XRAY's ROE of -0.41%. Regarding short-term risk, HBIO is more volatile compared to XRAY. This indicates higher risk in terms of short-term price fluctuations for HBIO.Check XRAY's competition here
LeMaitre Vascular, Inc. (NASDAQ: LMAT)
HBIO vs LMAT Comparison July 2026
Harvard Bioscience, Inc. (NASDAQ: HBIO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HBIO stands at 27.3M. In comparison, LMAT has a market cap of 2.2B. Regarding current trading prices, HBIO is priced at $6.00 on the NASDAQ, while LMAT trades at $95.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HBIO currently has a P/E ratio of -16.81, whereas LMAT's P/E ratio is 37.05. In terms of profitability, HBIO's ROE is -0.73%, compared to LMAT's ROE of +0.16%. Regarding short-term risk, HBIO is less volatile compared to LMAT. This indicates lower risk in terms of short-term price fluctuations for HBIO.Check LMAT's competition here
Pulse Biosciences, Inc. (NASDAQ: PLSE)
HBIO vs PLSE Comparison July 2026
Harvard Bioscience, Inc. (NASDAQ: HBIO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HBIO stands at 27.3M. In comparison, PLSE has a market cap of 2.1B. Regarding current trading prices, HBIO is priced at $6.00 on the NASDAQ, while PLSE trades at $30.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HBIO currently has a P/E ratio of -16.81, whereas PLSE's P/E ratio is -27.48. In terms of profitability, HBIO's ROE is -0.73%, compared to PLSE's ROE of -0.87%. Regarding short-term risk, HBIO is less volatile compared to PLSE. This indicates lower risk in terms of short-term price fluctuations for HBIO.Check PLSE's competition here
AtriCure, Inc. (NASDAQ: ATRC)
HBIO vs ATRC Comparison July 2026
Harvard Bioscience, Inc. (NASDAQ: HBIO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HBIO stands at 27.3M. In comparison, ATRC has a market cap of 1.8B. Regarding current trading prices, HBIO is priced at $6.00 on the NASDAQ, while ATRC trades at $35.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HBIO currently has a P/E ratio of -16.81, whereas ATRC's P/E ratio is 1088.20. In terms of profitability, HBIO's ROE is -0.73%, compared to ATRC's ROE of +0.02%. Regarding short-term risk, HBIO is less volatile compared to ATRC. This indicates lower risk in terms of short-term price fluctuations for HBIO.Check ATRC's competition here
BioLife Solutions, Inc. (NASDAQ: BLFS)
HBIO vs BLFS Comparison July 2026
Harvard Bioscience, Inc. (NASDAQ: HBIO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HBIO stands at 27.3M. In comparison, BLFS has a market cap of 1.5B. Regarding current trading prices, HBIO is priced at $6.00 on the NASDAQ, while BLFS trades at $29.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HBIO currently has a P/E ratio of -16.81, whereas BLFS's P/E ratio is -141.85. In terms of profitability, HBIO's ROE is -0.73%, compared to BLFS's ROE of -0.03%. Regarding short-term risk, HBIO is more volatile compared to BLFS. This indicates higher risk in terms of short-term price fluctuations for HBIO.Check BLFS's competition here
Azenta, Inc. (NASDAQ: AZTA)
HBIO vs AZTA Comparison July 2026
Harvard Bioscience, Inc. (NASDAQ: HBIO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HBIO stands at 27.3M. In comparison, AZTA has a market cap of 1.3B. Regarding current trading prices, HBIO is priced at $6.00 on the NASDAQ, while AZTA trades at $27.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HBIO currently has a P/E ratio of -16.81, whereas AZTA's P/E ratio is 60.82. In terms of profitability, HBIO's ROE is -0.73%, compared to AZTA's ROE of -0.11%. Regarding short-term risk, HBIO is less volatile compared to AZTA. This indicates lower risk in terms of short-term price fluctuations for HBIO.Check AZTA's competition here
Kestra Medical Technologies, Ltd. (NASDAQ: KMTS)
HBIO vs KMTS Comparison July 2026
Harvard Bioscience, Inc. (NASDAQ: HBIO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HBIO stands at 27.3M. In comparison, KMTS has a market cap of 1.2B. Regarding current trading prices, HBIO is priced at $6.00 on the NASDAQ, while KMTS trades at $21.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HBIO currently has a P/E ratio of -16.81, whereas KMTS's P/E ratio is -8.92. In terms of profitability, HBIO's ROE is -0.73%, compared to KMTS's ROE of -0.59%. Regarding short-term risk, HBIO is less volatile compared to KMTS. This indicates lower risk in terms of short-term price fluctuations for HBIO.Check KMTS's competition here
STAAR Surgical Company (NASDAQ: STAA)
HBIO vs STAA Comparison July 2026
Harvard Bioscience, Inc. (NASDAQ: HBIO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HBIO stands at 27.3M. In comparison, STAA has a market cap of 1.2B. Regarding current trading prices, HBIO is priced at $6.00 on the NASDAQ, while STAA trades at $23.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HBIO currently has a P/E ratio of -16.81, whereas STAA's P/E ratio is 41.02. In terms of profitability, HBIO's ROE is -0.73%, compared to STAA's ROE of -0.06%. Regarding short-term risk, HBIO is less volatile compared to STAA. This indicates lower risk in terms of short-term price fluctuations for HBIO.Check STAA's competition here
QuidelOrtho Corporation (NASDAQ: QDEL)
HBIO vs QDEL Comparison July 2026
Harvard Bioscience, Inc. (NASDAQ: HBIO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HBIO stands at 27.3M. In comparison, QDEL has a market cap of 1.1B. Regarding current trading prices, HBIO is priced at $6.00 on the NASDAQ, while QDEL trades at $16.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HBIO currently has a P/E ratio of -16.81, whereas QDEL's P/E ratio is 11.98. In terms of profitability, HBIO's ROE is -0.73%, compared to QDEL's ROE of -0.56%. Regarding short-term risk, HBIO is less volatile compared to QDEL. This indicates lower risk in terms of short-term price fluctuations for HBIO.Check QDEL's competition here
Atrion Corporation (NASDAQ: ATRI)
HBIO vs ATRI Comparison July 2026
Harvard Bioscience, Inc. (NASDAQ: HBIO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HBIO stands at 27.3M. In comparison, ATRI has a market cap of 809.4M. Regarding current trading prices, HBIO is priced at $6.00 on the NASDAQ, while ATRI trades at $459.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HBIO currently has a P/E ratio of -16.81, whereas ATRI's P/E ratio is 64.50. In terms of profitability, HBIO's ROE is -0.73%, compared to ATRI's ROE of +0.08%. Regarding short-term risk, HBIO is more volatile compared to ATRI. This indicates higher risk in terms of short-term price fluctuations for HBIO.Check ATRI's competition here
AngioDynamics, Inc. (NASDAQ: ANGO)
HBIO vs ANGO Comparison July 2026
Harvard Bioscience, Inc. (NASDAQ: HBIO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HBIO stands at 27.3M. In comparison, ANGO has a market cap of 561.7M. Regarding current trading prices, HBIO is priced at $6.00 on the NASDAQ, while ANGO trades at $13.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HBIO currently has a P/E ratio of -16.81, whereas ANGO's P/E ratio is -34.85. In terms of profitability, HBIO's ROE is -0.73%, compared to ANGO's ROE of -0.21%. Regarding short-term risk, HBIO is more volatile compared to ANGO. This indicates higher risk in terms of short-term price fluctuations for HBIO.Check ANGO's competition here
Anbio Biotechnology Class A Ordinary Shares (NASDAQ: NNNN)
HBIO vs NNNN Comparison July 2026
Harvard Bioscience, Inc. (NASDAQ: HBIO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HBIO stands at 27.3M. In comparison, NNNN has a market cap of 441.5M. Regarding current trading prices, HBIO is priced at $6.00 on the NASDAQ, while NNNN trades at $9.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HBIO currently has a P/E ratio of -16.81, whereas NNNN's P/E ratio is 145.38. In terms of profitability, HBIO's ROE is -0.73%, compared to NNNN's ROE of +0.27%. Regarding short-term risk, HBIO is less volatile compared to NNNN. This indicates lower risk in terms of short-term price fluctuations for HBIO.Check NNNN's competition here
OraSure Technologies, Inc. (NASDAQ: OSUR)
HBIO vs OSUR Comparison July 2026
Harvard Bioscience, Inc. (NASDAQ: HBIO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HBIO stands at 27.3M. In comparison, OSUR has a market cap of 273.3M. Regarding current trading prices, HBIO is priced at $6.00 on the NASDAQ, while OSUR trades at $3.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HBIO currently has a P/E ratio of -16.81, whereas OSUR's P/E ratio is -4.78. In terms of profitability, HBIO's ROE is -0.73%, compared to OSUR's ROE of -0.21%. Regarding short-term risk, HBIO is less volatile compared to OSUR. This indicates lower risk in terms of short-term price fluctuations for HBIO.Check OSUR's competition here
Sanara MedTech Inc. (NASDAQ: SMTI)
HBIO vs SMTI Comparison July 2026
Harvard Bioscience, Inc. (NASDAQ: HBIO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HBIO stands at 27.3M. In comparison, SMTI has a market cap of 234.2M. Regarding current trading prices, HBIO is priced at $6.00 on the NASDAQ, while SMTI trades at $25.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HBIO currently has a P/E ratio of -16.81, whereas SMTI's P/E ratio is -426.00. In terms of profitability, HBIO's ROE is -0.73%, compared to SMTI's ROE of -2.46%. Regarding short-term risk, HBIO is more volatile compared to SMTI. This indicates higher risk in terms of short-term price fluctuations for HBIO.Check SMTI's competition here
Utah Medical Products, Inc. (NASDAQ: UTMD)
HBIO vs UTMD Comparison July 2026
Harvard Bioscience, Inc. (NASDAQ: HBIO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HBIO stands at 27.3M. In comparison, UTMD has a market cap of 213.8M. Regarding current trading prices, HBIO is priced at $6.00 on the NASDAQ, while UTMD trades at $67.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HBIO currently has a P/E ratio of -16.81, whereas UTMD's P/E ratio is 19.86. In terms of profitability, HBIO's ROE is -0.73%, compared to UTMD's ROE of +0.09%. Regarding short-term risk, HBIO is less volatile compared to UTMD. This indicates lower risk in terms of short-term price fluctuations for HBIO.Check UTMD's competition here
InfuSystem Holdings, Inc. (AMEX: INFU)
HBIO vs INFU Comparison July 2026
Harvard Bioscience, Inc. (NASDAQ: HBIO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HBIO stands at 27.3M. In comparison, INFU has a market cap of 183.9M. Regarding current trading prices, HBIO is priced at $6.00 on the NASDAQ, while INFU trades at $9.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HBIO currently has a P/E ratio of -16.81, whereas INFU's P/E ratio is 23.97. In terms of profitability, HBIO's ROE is -0.73%, compared to INFU's ROE of +0.14%. Regarding short-term risk, HBIO is less volatile compared to INFU. This indicates lower risk in terms of short-term price fluctuations for HBIO.Check INFU's competition here
KORU Medical Systems, Inc. (NASDAQ: KRMD)
HBIO vs KRMD Comparison July 2026
Harvard Bioscience, Inc. (NASDAQ: HBIO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HBIO stands at 27.3M. In comparison, KRMD has a market cap of 175.9M. Regarding current trading prices, HBIO is priced at $6.00 on the NASDAQ, while KRMD trades at $3.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HBIO currently has a P/E ratio of -16.81, whereas KRMD's P/E ratio is -95.75. In terms of profitability, HBIO's ROE is -0.73%, compared to KRMD's ROE of -0.14%. Regarding short-term risk, HBIO is less volatile compared to KRMD. This indicates lower risk in terms of short-term price fluctuations for HBIO.Check KRMD's competition here
Pro-Dex, Inc. (NASDAQ: PDEX)
HBIO vs PDEX Comparison July 2026
Harvard Bioscience, Inc. (NASDAQ: HBIO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HBIO stands at 27.3M. In comparison, PDEX has a market cap of 175.4M. Regarding current trading prices, HBIO is priced at $6.00 on the NASDAQ, while PDEX trades at $54.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HBIO currently has a P/E ratio of -16.81, whereas PDEX's P/E ratio is 19.34. In terms of profitability, HBIO's ROE is -0.73%, compared to PDEX's ROE of +0.29%. Regarding short-term risk, HBIO is less volatile compared to PDEX. This indicates lower risk in terms of short-term price fluctuations for HBIO.Check PDEX's competition here
Microbot Medical Inc. (NASDAQ: MBOT)
HBIO vs MBOT Comparison July 2026
Harvard Bioscience, Inc. (NASDAQ: HBIO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HBIO stands at 27.3M. In comparison, MBOT has a market cap of 77.9M. Regarding current trading prices, HBIO is priced at $6.00 on the NASDAQ, while MBOT trades at $1.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HBIO currently has a P/E ratio of -16.81, whereas MBOT's P/E ratio is -6.58. In terms of profitability, HBIO's ROE is -0.73%, compared to MBOT's ROE of -0.22%. Regarding short-term risk, HBIO is less volatile compared to MBOT. This indicates lower risk in terms of short-term price fluctuations for HBIO.Check MBOT's competition here
Akoya Biosciences, Inc. (NASDAQ: AKYA)
HBIO vs AKYA Comparison July 2026
Harvard Bioscience, Inc. (NASDAQ: HBIO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HBIO stands at 27.3M. In comparison, AKYA has a market cap of 64.4M. Regarding current trading prices, HBIO is priced at $6.00 on the NASDAQ, while AKYA trades at $1.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HBIO currently has a P/E ratio of -16.81, whereas AKYA's P/E ratio is -1.34. In terms of profitability, HBIO's ROE is -0.73%, compared to AKYA's ROE of -1.80%. Regarding short-term risk, HBIO is more volatile compared to AKYA. This indicates higher risk in terms of short-term price fluctuations for HBIO.Check AKYA's competition here
SkyAI, Inc. (NASDAQ: STSS)
HBIO vs STSS Comparison July 2026
Harvard Bioscience, Inc. (NASDAQ: HBIO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HBIO stands at 27.3M. In comparison, STSS has a market cap of 58.4M. Regarding current trading prices, HBIO is priced at $6.00 on the NASDAQ, while STSS trades at $1.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HBIO currently has a P/E ratio of -16.81, whereas STSS's P/E ratio is -0.02. In terms of profitability, HBIO's ROE is -0.73%, compared to STSS's ROE of -1.66%. Regarding short-term risk, HBIO is less volatile compared to STSS. This indicates lower risk in terms of short-term price fluctuations for HBIO.Check STSS's competition here
Daxor Corporation (NASDAQ: DXR)
HBIO vs DXR Comparison July 2026
Harvard Bioscience, Inc. (NASDAQ: HBIO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HBIO stands at 27.3M. In comparison, DXR has a market cap of 52.7M. Regarding current trading prices, HBIO is priced at $6.00 on the NASDAQ, while DXR trades at $10.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HBIO currently has a P/E ratio of -16.81, whereas DXR's P/E ratio is 27.33. In terms of profitability, HBIO's ROE is -0.73%, compared to DXR's ROE of +0.22%. Regarding short-term risk, HBIO is more volatile compared to DXR. This indicates higher risk in terms of short-term price fluctuations for HBIO.Check DXR's competition here
Singular Genomics Systems, Inc. (NASDAQ: OMIC)
HBIO vs OMIC Comparison July 2026
Harvard Bioscience, Inc. (NASDAQ: HBIO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HBIO stands at 27.3M. In comparison, OMIC has a market cap of 50.8M. Regarding current trading prices, HBIO is priced at $6.00 on the NASDAQ, while OMIC trades at $20.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HBIO currently has a P/E ratio of -16.81, whereas OMIC's P/E ratio is -0.58. In terms of profitability, HBIO's ROE is -0.73%, compared to OMIC's ROE of -0.43%. Regarding short-term risk, HBIO is more volatile compared to OMIC. This indicates higher risk in terms of short-term price fluctuations for HBIO.Check OMIC's competition here
GlucoTrack, Inc. (NASDAQ: IGAP)
HBIO vs IGAP Comparison July 2026
Harvard Bioscience, Inc. (NASDAQ: HBIO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HBIO stands at 27.3M. In comparison, IGAP has a market cap of 50.2M. Regarding current trading prices, HBIO is priced at $6.00 on the NASDAQ, while IGAP trades at $3.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HBIO currently has a P/E ratio of -16.81, whereas IGAP's P/E ratio is -10.52. In terms of profitability, HBIO's ROE is -0.73%, compared to IGAP's ROE of -0.86%. Regarding short-term risk, HBIO is more volatile compared to IGAP. This indicates higher risk in terms of short-term price fluctuations for HBIO.Check IGAP's competition here
Nephros, Inc. (NASDAQ: NEPH)
HBIO vs NEPH Comparison July 2026
Harvard Bioscience, Inc. (NASDAQ: HBIO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HBIO stands at 27.3M. In comparison, NEPH has a market cap of 38.6M. Regarding current trading prices, HBIO is priced at $6.00 on the NASDAQ, while NEPH trades at $3.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HBIO currently has a P/E ratio of -16.81, whereas NEPH's P/E ratio is 50.86. In terms of profitability, HBIO's ROE is -0.73%, compared to NEPH's ROE of +0.08%. Regarding short-term risk, HBIO is less volatile compared to NEPH. This indicates lower risk in terms of short-term price fluctuations for HBIO.Check NEPH's competition here
Milestone Scientific Inc. (AMEX: MLSS)
HBIO vs MLSS Comparison July 2026
Harvard Bioscience, Inc. (NASDAQ: HBIO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HBIO stands at 27.3M. In comparison, MLSS has a market cap of 34.5M. Regarding current trading prices, HBIO is priced at $6.00 on the NASDAQ, while MLSS trades at $0.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HBIO currently has a P/E ratio of -16.81, whereas MLSS's P/E ratio is -6.50. In terms of profitability, HBIO's ROE is -0.73%, compared to MLSS's ROE of -1.66%. Regarding short-term risk, HBIO is less volatile compared to MLSS. This indicates lower risk in terms of short-term price fluctuations for HBIO.Check MLSS's competition here
Precision Optics Corporation, Inc. (NASDAQ: POCI)
HBIO vs POCI Comparison July 2026
Harvard Bioscience, Inc. (NASDAQ: HBIO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HBIO stands at 27.3M. In comparison, POCI has a market cap of 33.8M. Regarding current trading prices, HBIO is priced at $6.00 on the NASDAQ, while POCI trades at $4.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HBIO currently has a P/E ratio of -16.81, whereas POCI's P/E ratio is -6.07. In terms of profitability, HBIO's ROE is -0.73%, compared to POCI's ROE of -0.37%. Regarding short-term risk, HBIO is less volatile compared to POCI. This indicates lower risk in terms of short-term price fluctuations for HBIO.Check POCI's competition here
SmileDirectClub, Inc. (NASDAQ: SDC)
HBIO vs SDC Comparison July 2026
Harvard Bioscience, Inc. (NASDAQ: HBIO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HBIO stands at 27.3M. In comparison, SDC has a market cap of 29.1M. Regarding current trading prices, HBIO is priced at $6.00 on the NASDAQ, while SDC trades at $0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HBIO currently has a P/E ratio of -16.81, whereas SDC's P/E ratio is -0.03. In terms of profitability, HBIO's ROE is -0.73%, compared to SDC's ROE of -1.96%. Regarding short-term risk, HBIO is less volatile compared to SDC. This indicates lower risk in terms of short-term price fluctuations for HBIO.Check SDC's competition here
Invacare Corporation (NYSE: IVC)
HBIO vs IVC Comparison July 2026
Harvard Bioscience, Inc. (NASDAQ: HBIO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HBIO stands at 27.3M. In comparison, IVC has a market cap of 24.9M. Regarding current trading prices, HBIO is priced at $6.00 on the NASDAQ, while IVC trades at $0.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HBIO currently has a P/E ratio of -16.81, whereas IVC's P/E ratio is -0.79. In terms of profitability, HBIO's ROE is -0.73%, compared to IVC's ROE of -0.46%. Regarding short-term risk, HBIO is less volatile compared to IVC. This indicates lower risk in terms of short-term price fluctuations for HBIO.Check IVC's competition here
Retractable Technologies, Inc. (AMEX: RVP)
HBIO vs RVP Comparison July 2026
Harvard Bioscience, Inc. (NASDAQ: HBIO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HBIO stands at 27.3M. In comparison, RVP has a market cap of 20.4M. Regarding current trading prices, HBIO is priced at $6.00 on the NASDAQ, while RVP trades at $0.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HBIO currently has a P/E ratio of -16.81, whereas RVP's P/E ratio is -2.06. In terms of profitability, HBIO's ROE is -0.73%, compared to RVP's ROE of -0.08%. Regarding short-term risk, HBIO is more volatile compared to RVP. This indicates higher risk in terms of short-term price fluctuations for HBIO.Check RVP's competition here
Jin Medical International Ltd. (NASDAQ: ZJYL)
HBIO vs ZJYL Comparison July 2026
Harvard Bioscience, Inc. (NASDAQ: HBIO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HBIO stands at 27.3M. In comparison, ZJYL has a market cap of 16M. Regarding current trading prices, HBIO is priced at $6.00 on the NASDAQ, while ZJYL trades at $2.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HBIO currently has a P/E ratio of -16.81, whereas ZJYL's P/E ratio is 12.75. In terms of profitability, HBIO's ROE is -0.73%, compared to ZJYL's ROE of +0.04%. Regarding short-term risk, HBIO is less volatile compared to ZJYL. This indicates lower risk in terms of short-term price fluctuations for HBIO.Check ZJYL's competition here
Femasys Inc. (NASDAQ: FEMY)
HBIO vs FEMY Comparison July 2026
Harvard Bioscience, Inc. (NASDAQ: HBIO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HBIO stands at 27.3M. In comparison, FEMY has a market cap of 11.2M. Regarding current trading prices, HBIO is priced at $6.00 on the NASDAQ, while FEMY trades at $3.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HBIO currently has a P/E ratio of -16.81, whereas FEMY's P/E ratio is -10.25. In terms of profitability, HBIO's ROE is -0.73%, compared to FEMY's ROE of -2.58%. Regarding short-term risk, HBIO is less volatile compared to FEMY. This indicates lower risk in terms of short-term price fluctuations for HBIO.Check FEMY's competition here
Regentis Biomaterials Ltd. (AMEX: RGNT)
HBIO vs RGNT Comparison July 2026
Harvard Bioscience, Inc. (NASDAQ: HBIO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HBIO stands at 27.3M. In comparison, RGNT has a market cap of 7.8M. Regarding current trading prices, HBIO is priced at $6.00 on the NASDAQ, while RGNT trades at $1.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HBIO currently has a P/E ratio of -16.81, whereas RGNT's P/E ratio is -0.08. In terms of profitability, HBIO's ROE is -0.73%, compared to RGNT's ROE of N/A. Regarding short-term risk, HBIO is less volatile compared to RGNT. This indicates lower risk in terms of short-term price fluctuations for HBIO.Check RGNT's competition here
NanoString Technologies, Inc. (NASDAQ: NSTG)
HBIO vs NSTG Comparison July 2026
Harvard Bioscience, Inc. (NASDAQ: HBIO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HBIO stands at 27.3M. In comparison, NSTG has a market cap of 5.1M. Regarding current trading prices, HBIO is priced at $6.00 on the NASDAQ, while NSTG trades at $0.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HBIO currently has a P/E ratio of -16.81, whereas NSTG's P/E ratio is -0.03. In terms of profitability, HBIO's ROE is -0.73%, compared to NSTG's ROE of -1.43%. Regarding short-term risk, HBIO is less volatile compared to NSTG. This indicates lower risk in terms of short-term price fluctuations for HBIO.Check NSTG's competition here
NEXGEL, Inc. (NASDAQ: NXGL)
HBIO vs NXGL Comparison July 2026
Harvard Bioscience, Inc. (NASDAQ: HBIO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HBIO stands at 27.3M. In comparison, NXGL has a market cap of 4M. Regarding current trading prices, HBIO is priced at $6.00 on the NASDAQ, while NXGL trades at $0.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HBIO currently has a P/E ratio of -16.81, whereas NXGL's P/E ratio is -1.13. In terms of profitability, HBIO's ROE is -0.73%, compared to NXGL's ROE of -0.70%. Regarding short-term risk, HBIO is less volatile compared to NXGL. This indicates lower risk in terms of short-term price fluctuations for HBIO.Check NXGL's competition here
Predictive Oncology Inc. (NASDAQ: POAI)
HBIO vs POAI Comparison July 2026
Harvard Bioscience, Inc. (NASDAQ: HBIO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HBIO stands at 27.3M. In comparison, POAI has a market cap of 3.6M. Regarding current trading prices, HBIO is priced at $6.00 on the NASDAQ, while POAI trades at $4.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HBIO currently has a P/E ratio of -16.81, whereas POAI's P/E ratio is -0.03. In terms of profitability, HBIO's ROE is -0.73%, compared to POAI's ROE of -107.05%. Regarding short-term risk, HBIO is less volatile compared to POAI. This indicates lower risk in terms of short-term price fluctuations for HBIO.Check POAI's competition here
Lucyd, Inc (NASDAQ: LUCY)
HBIO vs LUCY Comparison July 2026
Harvard Bioscience, Inc. (NASDAQ: HBIO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HBIO stands at 27.3M. In comparison, LUCY has a market cap of 2.6M. Regarding current trading prices, HBIO is priced at $6.00 on the NASDAQ, while LUCY trades at $0.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HBIO currently has a P/E ratio of -16.81, whereas LUCY's P/E ratio is -0.39. In terms of profitability, HBIO's ROE is -0.73%, compared to LUCY's ROE of -0.83%. Regarding short-term risk, HBIO is less volatile compared to LUCY. This indicates lower risk in terms of short-term price fluctuations for HBIO.Check LUCY's competition here
Meihua International Medical Technologies Co., Ltd. (NASDAQ: MHUA)
HBIO vs MHUA Comparison July 2026
Harvard Bioscience, Inc. (NASDAQ: HBIO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HBIO stands at 27.3M. In comparison, MHUA has a market cap of 2.4M. Regarding current trading prices, HBIO is priced at $6.00 on the NASDAQ, while MHUA trades at $7.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HBIO currently has a P/E ratio of -16.81, whereas MHUA's P/E ratio is 0.25. In terms of profitability, HBIO's ROE is -0.73%, compared to MHUA's ROE of +0.07%. Regarding short-term risk, HBIO is more volatile compared to MHUA. This indicates higher risk in terms of short-term price fluctuations for HBIO.Check MHUA's competition here
NEXGEL, Inc. (NASDAQ: NXGLW)
HBIO vs NXGLW Comparison July 2026
Harvard Bioscience, Inc. (NASDAQ: HBIO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HBIO stands at 27.3M. In comparison, NXGLW has a market cap of 1.8M. Regarding current trading prices, HBIO is priced at $6.00 on the NASDAQ, while NXGLW trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HBIO currently has a P/E ratio of -16.81, whereas NXGLW's P/E ratio is -0.06. In terms of profitability, HBIO's ROE is -0.73%, compared to NXGLW's ROE of -0.70%. Regarding short-term risk, HBIO is more volatile compared to NXGLW. This indicates higher risk in terms of short-term price fluctuations for HBIO.Check NXGLW's competition here
G Medical Innovations Holdings Ltd (NASDAQ: GMVD)
HBIO vs GMVD Comparison July 2026
Harvard Bioscience, Inc. (NASDAQ: HBIO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HBIO stands at 27.3M. In comparison, GMVD has a market cap of 1.8M. Regarding current trading prices, HBIO is priced at $6.00 on the NASDAQ, while GMVD trades at $0.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HBIO currently has a P/E ratio of -16.81, whereas GMVD's P/E ratio is -0.01. In terms of profitability, HBIO's ROE is -0.73%, compared to GMVD's ROE of +2.09%. Regarding short-term risk, HBIO is less volatile compared to GMVD. This indicates lower risk in terms of short-term price fluctuations for HBIO.Check GMVD's competition here
G Medical Innovations Holdings Ltd (NASDAQ: GMVDW)
HBIO vs GMVDW Comparison July 2026
Harvard Bioscience, Inc. (NASDAQ: HBIO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HBIO stands at 27.3M. In comparison, GMVDW has a market cap of 1.8M. Regarding current trading prices, HBIO is priced at $6.00 on the NASDAQ, while GMVDW trades at $7.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HBIO currently has a P/E ratio of -16.81, whereas GMVDW's P/E ratio is N/A. In terms of profitability, HBIO's ROE is -0.73%, compared to GMVDW's ROE of +2.09%. Regarding short-term risk, HBIO is less volatile compared to GMVDW. This indicates lower risk in terms of short-term price fluctuations for HBIO.Check GMVDW's competition here
Avinger, Inc. (NASDAQ: AVGR)
HBIO vs AVGR Comparison July 2026
Harvard Bioscience, Inc. (NASDAQ: HBIO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HBIO stands at 27.3M. In comparison, AVGR has a market cap of 1.5M. Regarding current trading prices, HBIO is priced at $6.00 on the NASDAQ, while AVGR trades at $0.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HBIO currently has a P/E ratio of -16.81, whereas AVGR's P/E ratio is -0.05. In terms of profitability, HBIO's ROE is -0.73%, compared to AVGR's ROE of +17.82%. Regarding short-term risk, HBIO is less volatile compared to AVGR. This indicates lower risk in terms of short-term price fluctuations for HBIO.Check AVGR's competition here
Lucyd, Inc (NASDAQ: LUCYW)
HBIO vs LUCYW Comparison July 2026
Harvard Bioscience, Inc. (NASDAQ: HBIO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HBIO stands at 27.3M. In comparison, LUCYW has a market cap of 296.1K. Regarding current trading prices, HBIO is priced at $6.00 on the NASDAQ, while LUCYW trades at $0.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HBIO currently has a P/E ratio of -16.81, whereas LUCYW's P/E ratio is -0.00. In terms of profitability, HBIO's ROE is -0.73%, compared to LUCYW's ROE of -0.83%. Regarding short-term risk, HBIO is less volatile compared to LUCYW. This indicates lower risk in terms of short-term price fluctuations for HBIO.Check LUCYW's competition here
GlucoTrack, Inc. (NASDAQ: GCTK)
HBIO vs GCTK Comparison July 2026
Harvard Bioscience, Inc. (NASDAQ: HBIO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HBIO stands at 27.3M. In comparison, GCTK has a market cap of 165.2K. Regarding current trading prices, HBIO is priced at $6.00 on the NASDAQ, while GCTK trades at $0.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HBIO currently has a P/E ratio of -16.81, whereas GCTK's P/E ratio is -0.01. In terms of profitability, HBIO's ROE is -0.73%, compared to GCTK's ROE of -5.82%. Regarding short-term risk, HBIO is less volatile compared to GCTK. This indicates lower risk in terms of short-term price fluctuations for HBIO.Check GCTK's competition here
Apria, Inc. (NASDAQ: APR)
HBIO vs APR Comparison July 2026
Harvard Bioscience, Inc. (NASDAQ: HBIO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HBIO stands at 27.3M. In comparison, APR has a market cap of 0. Regarding current trading prices, HBIO is priced at $6.00 on the NASDAQ, while APR trades at $37.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HBIO currently has a P/E ratio of -16.81, whereas APR's P/E ratio is 22.59. In terms of profitability, HBIO's ROE is -0.73%, compared to APR's ROE of +9.81%. Regarding short-term risk, HBIO is more volatile compared to APR. This indicates higher risk in terms of short-term price fluctuations for HBIO.Check APR's competition here
IntriCon Corporation (NASDAQ: IIN)
HBIO vs IIN Comparison July 2026
Harvard Bioscience, Inc. (NASDAQ: HBIO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HBIO stands at 27.3M. In comparison, IIN has a market cap of 0. Regarding current trading prices, HBIO is priced at $6.00 on the NASDAQ, while IIN trades at $24.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HBIO currently has a P/E ratio of -16.81, whereas IIN's P/E ratio is 226.45. In terms of profitability, HBIO's ROE is -0.73%, compared to IIN's ROE of -0.00%. Regarding short-term risk, HBIO is more volatile compared to IIN. This indicates higher risk in terms of short-term price fluctuations for HBIO.Check IIN's competition here
Analogic Corporation (NASDAQ: ALOG)
HBIO vs ALOG Comparison July 2026
Harvard Bioscience, Inc. (NASDAQ: HBIO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HBIO stands at 27.3M. In comparison, ALOG has a market cap of 0. Regarding current trading prices, HBIO is priced at $6.00 on the NASDAQ, while ALOG trades at $83.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HBIO currently has a P/E ratio of -16.81, whereas ALOG's P/E ratio is 40.93. In terms of profitability, HBIO's ROE is -0.73%, compared to ALOG's ROE of -0.15%. Regarding short-term risk, HBIO is more volatile compared to ALOG. This indicates higher risk in terms of short-term price fluctuations for HBIO.Check ALOG's competition here
Antares Pharma, Inc. (NASDAQ: ATRS)
HBIO vs ATRS Comparison July 2026
Harvard Bioscience, Inc. (NASDAQ: HBIO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HBIO stands at 27.3M. In comparison, ATRS has a market cap of 0. Regarding current trading prices, HBIO is priced at $6.00 on the NASDAQ, while ATRS trades at $5.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HBIO currently has a P/E ratio of -16.81, whereas ATRS's P/E ratio is 14.95. In terms of profitability, HBIO's ROE is -0.73%, compared to ATRS's ROE of +0.31%. Regarding short-term risk, HBIO is more volatile compared to ATRS. This indicates higher risk in terms of short-term price fluctuations for HBIO.Check ATRS's competition here
Invuity, Inc. (NASDAQ: IVTY)
HBIO vs IVTY Comparison July 2026
Harvard Bioscience, Inc. (NASDAQ: HBIO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HBIO stands at 27.3M. In comparison, IVTY has a market cap of 0. Regarding current trading prices, HBIO is priced at $6.00 on the NASDAQ, while IVTY trades at $7.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HBIO currently has a P/E ratio of -16.81, whereas IVTY's P/E ratio is -3.80. In terms of profitability, HBIO's ROE is -0.73%, compared to IVTY's ROE of -2.40%. Regarding short-term risk, HBIO is more volatile compared to IVTY. This indicates higher risk in terms of short-term price fluctuations for HBIO.Check IVTY's competition here
Hill-Rom Holdings, Inc. (NYSE: HRC)
HBIO vs HRC Comparison July 2026
Harvard Bioscience, Inc. (NASDAQ: HBIO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HBIO stands at 27.3M. In comparison, HRC has a market cap of 0. Regarding current trading prices, HBIO is priced at $6.00 on the NASDAQ, while HRC trades at $155.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HBIO currently has a P/E ratio of -16.81, whereas HRC's P/E ratio is 41.92. In terms of profitability, HBIO's ROE is -0.73%, compared to HRC's ROE of +0.14%. Regarding short-term risk, HBIO is more volatile compared to HRC. This indicates higher risk in terms of short-term price fluctuations for HBIO.Check HRC's competition here